الفهرس 
Epidemiology and Genetic Basis of ALLOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
Background: Heart disease and cancer are the leading causes of death in older adults. Concerns
regarding cardiotoxicity of anticancer agents may lead to under-treatment, resulting in
suboptimal outcomes.
Aim: to assess the prevalence and risk factors of cardiotoxicity in elderly patients with cancer.
Patients and Methods: The study sample comprised one hundred (100) elderly participants,
men and women, sixty years and above. All participants included in the study were subjected to:
comprehensive geriatric assessment (CGA), laboratory investigations (including: lipid profile,
fasting blood glucose, C-reactive protein), echocardiography (ECHO) and electrocardiogram
(ECG).
Results: In the current study, the prevalence of cardiotoxicity was 57%. Participants who
experienced cardiotoxicity were older, had higher smoking index, lower body mass index, and
longer cancer duration. They had higher prevalence of diabetes, hypertension and dyslipidemia
and had higher mean value of C-reactive protein. Participants who had received certain
chemotherapy agents (Anthracycline, 5-Fluorouracil, Capecitabine, Arsenic trioxide, and
Lapatinib), certain targeted therapy agents (Pertuzumab and Trastuzumab); and those who
received radiotherapy (most commonly radiotherapy to the chest) were more liable for
cardiotoxicity. Cardiotoxicity was associated with depression, malnutrition, and functional
decline of the affected patients.
Conclusion: Cardiotoxicity is common in elderly cancer patients. It is associated with risk
factors as older age, higher smoking index, longer cancer duration, higher prevalence of
hypertension, diabetes and dyslipidemia, and treatment with certain anticancer agents.
Comprehensive geriatric assessment is essential in elderly cancer patients